1-12 of 12
Toshimitsu Uenaka
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models

Available to Purchase
Shigehiro Yagishita, Sho Sato, Daisuke Shintani, Tadaaki Nishikawa, Aiko Ogasawara, Masanori Yasuda, Hironori Ishii, Keiji Furuuchi, Toshimitsu Uenaka, Hiroshi Yoshida, Kosei Hasegawa, Akinobu Hamada
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther OF1–OF13.
https://doi.org/10.1158/1535-7163.MCT-25-0035
Published: 01 July 2025
View article titled, Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
Open the PDF for Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models in another window
Includes: Supplementary data
Journal Articles

Potential Mechanisms of Interstitial Lung Disease Induced by Antibody–Drug Conjugates Based on Quantitative Analysis of Drug Distribution

Open Access
Shigehiro Koganemaru, Hirobumi Fuchigami, Chihiro Morizono, Hiroko Shinohara, Yasutoshi Kuboki, Keiji Furuuchi, Toshimitsu Uenaka, Toshihiko Doi, Masahiro Yasunaga
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2025) 24 (2): 242–250.
https://doi.org/10.1158/1535-7163.MCT-24-0267
Published: 04 February 2025
View article titled, Potential Mechanisms of Interstitial Lung Disease Induced by Antibody–Drug Conjugates Based on Quantitative Analysis of Drug Distribution
Open the PDF for Potential Mechanisms of Interstitial Lung Disease Induced by Antibody–Drug Conjugates Based on Quantitative Analysis of Drug Distribution in another window
Includes: Supplementary data
Journal Articles

Abstract C008: Phase I biomarker analysis of farletuzumab ecteribulin (FZEC), formerly MORAb-202, effects on cancer responses in patients with platinum resistant ovarian cancer

Free
Yan Zhang, Bob Zimmermann, Shuyu Li, Toshimitsu Uenaka, Keiji Furuuchi, Kan Yonemori, Toshio Shimizu, Shin Nishio, Mayu Yunokawa, Koji Matsumoto, Kazuhiro Takehara, Kosei Hasegawa, Yasuyuki Hirashima, Hidenori Kato, Yohei Otake, Takuma Miura, Junji Matsui, Meijuan Li
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C008.
https://doi.org/10.1158/1535-7163.TARG-23-C008
Published: 01 December 2023
View article titled, Abstract C008: Phase I biomarker analysis of farletuzumab ecteribulin (FZEC), formerly MORAb-202, effects on cancer responses in patients with platinum resistant ovarian cancer
Journal Articles

MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity

Free
Xin Cheng, Jing Li, Keigo Tanaka, Utpal Majumder, Andrew Z. Milinichik, Arielle C. Verdi, Christopher J. Maddage, Katherine A. Rybinski, Shawn Fernando, Danielle Fernando, Megan Kuc, Keiji Furuuchi, Frank Fang, Toshimitsu Uenaka, Luigi Grasso, Earl F. Albone
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (12): 2665–2675.
https://doi.org/10.1158/1535-7163.MCT-17-1215
Published: 03 December 2018
View article titled, MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity
Open the PDF for MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity in another window
Includes: Supplementary data
Journal Articles

Abstract B115: MORAb-202: a folate receptor alpha (FRA)-targeting antibody-drug conjugate, exhibiting targeted antitumor activity and bystander elimination of cancer-associated fibroblasts

Free
Katherine A. Rybinski, Christopher Maddage, Xin Cheng, Earl Albone, Luigi Grasso, Keiji Furuuchi, Toshimitsu Uenaka
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B115.
https://doi.org/10.1158/1535-7163.TARG-17-B115
Published: 01 January 2018
View article titled, Abstract B115: MORAb-202: a folate receptor alpha (FRA)-targeting antibody-drug conjugate, exhibiting targeted antitumor activity and bystander elimination of cancer-associated fibroblasts
Journal Articles

Abstract B107: Antitumor activity of new antibody-drug conjugate with eribulin in triple-negative breast cancer PDX

Free
Marc Hillairet de Boisferon, Caroline Mignard, Coralie Durix, Toshimitsu Uenaka, Katherine Rybinski, Xin Cheng, Keiji Furuuchi, Eart Albone
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B107.
https://doi.org/10.1158/1535-7163.TARG-17-B107
Published: 01 January 2018
View article titled, Abstract B107: Antitumor activity of new antibody-drug conjugate with eribulin in triple-negative breast cancer PDX
Journal Articles

E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models

Free
Saori Watanabe Miyano, Yuji Yamamoto, Kotaro Kodama, Yukiko Miyajima, Masaki Mikamoto, Takayuki Nakagawa, Hiroko Kuramochi, Setsuo Funasaka, Satoshi Nagao, Naoko Hata Sugi, Kiyoshi Okamoto, Yukinori Minoshima, Yusuke Nakatani, Yuki Karoji, Isao Ohashi, Yoshinobu Yamane, Toshimi Okada, Tomohiro Matsushima, Junji Matsui, Masao Iwata, Toshimitsu Uenaka, Akihiko Tsuruoka
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (11): 2630–2639.
https://doi.org/10.1158/1535-7163.MCT-16-0261
Published: 01 November 2016
View article titled, E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
Open the PDF for E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Apratoxin A Shows Novel Pancreas-Targeting Activity through the Binding of Sec 61

Free
Kuan-Chun Huang, Zhihong Chen, Yimin Jiang, Sandeep Akare, Donna Kolber-Simonds, Krista Condon, Sergei Agoulnik, Karen Tendyke, Yongchun Shen, Kuo-Ming Wu, Steven Mathieu, Hyeong-wook Choi, Xiaojie Zhu, Hajime Shimizu, Yoshihiko Kotake, William H. Gerwick, Toshimitsu Uenaka, Mary Woodall-Jappe, Kenichi Nomoto
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (6): 1208–1216.
https://doi.org/10.1158/1535-7163.MCT-15-0648
Published: 02 June 2016
View article titled, Apratoxin A Shows Novel Pancreas-Targeting Activity through the Binding of Sec 61
Open the PDF for Apratoxin A Shows Novel Pancreas-Targeting Activity through the Binding of Sec 61 in another window
Includes: Supplementary data
Journal Articles

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma

Free
Sarah K. Knutson, Satoshi Kawano, Yukinori Minoshima, Natalie M. Warholic, Kuan-Chun Huang, Yonghong Xiao, Tadashi Kadowaki, Mai Uesugi, Galina Kuznetsov, Namita Kumar, Tim J. Wigle, Christine R. Klaus, Christina J. Allain, Alejandra Raimondi, Nigel J. Waters, Jesse J. Smith, Margaret Porter-Scott, Richard Chesworth, Mikel P. Moyer, Robert A. Copeland, Victoria M. Richon, Toshimitsu Uenaka, Roy M. Pollock, Kevin W. Kuntz, Akira Yokoi, Heike Keilhack
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2014) 13 (4): 842–854.
https://doi.org/10.1158/1535-7163.MCT-13-0773
Published: 06 April 2014
View article titled, Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
Open the PDF for Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer

Free
Takayuki Nakagawa, Shinji Takeuchi, Tadaaki Yamada, Shigeki Nanjo, Daisuke Ishikawa, Takako Sano, Kenji Kita, Takahiro Nakamura, Kunio Matsumoto, Kenichi Suda, Tetsuya Mitsudomi, Yoshitaka Sekido, Toshimitsu Uenaka, Seiji Yano
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (10): 2149–2157.
https://doi.org/10.1158/1535-7163.MCT-12-0195
Published: 09 October 2012
View article titled, Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
Open the PDF for Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor

Free
Hirokazu Ogino, Masaki Hanibuchi, Soji Kakiuchi, Van The Trung, Hisatsugu Goto, Kenji Ikuta, Tadaaki Yamada, Hisanori Uehara, Akihiko Tsuruoka, Toshimitsu Uenaka, Wei Wang, Qi Li, Shinji Takeuchi, Seiji Yano, Yasuhiko Nishioka, Saburo Sone
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (7): 1218–1228.
https://doi.org/10.1158/1535-7163.MCT-10-0707
Published: 06 July 2011
View article titled, E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor
Open the PDF for E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor in another window
Includes: Supplementary data
Journal Articles

Antitumor Activity of ER-37328, a Novel Carbazole Topoisomerase II Inhibitor

Free
Katsuji Nakamura, Hiroyuki Sugumi, Atsumi Yamaguchi, Toshimitsu Uenaka, Yoshihiko Kotake, Toshimi Okada, Junichi Kamata, Jun Niijima, Takeshi Nagasu, Nozomu Koyanagi, Hiroshi Yoshino, Kyosuke Kitoh, Kentaro Yoshimatsu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2002) 1 (3): 169–175.
Published: 01 January 2002
View article titled, Antitumor Activity of ER-37328, a Novel Carbazole Topoisomerase II Inhibitor
Open the PDF for Antitumor Activity of ER-37328, a Novel Carbazole Topoisomerase II Inhibitor in another window